

Special Issue

Herpes Simplex Virus Infection, Immunity, and Vaccine Development

Message from the Guest Editors

Herpes Simplex Virus (HSV) infections affect people around the world, with HSV-1 and HSV-2 causing significant morbidity through recurrent oral-facial, ocular, and genital lesions. Despite decades of pre-clinical and clinical research, no licensed HSV vaccines or immunotherapeutic agents are currently available. We encourage submissions on the following topics:

- Herpes simplex infection and immunity in animal models and humans
- Multi-omics data to better phenotype, differentiate, and classify immune responses
- Immunological and virological factors contributing protection or exacerbating recurrent herpes infection and disease
- Immune regulation, immune evasion, immune checkpoints, and immuno-regulatory pathways
- Pre-clinical and clinical evaluation of HSV vaccine and immunotherapeutic candidates
- Innovative vaccine and immunotherapeutic platforms, adjuvants, and delivery systems
- Identification of protective B- and T-cell antigens/epitopes
- Innate and adaptive immunological correlates of protection
- Therapeutic vaccination strategies for individuals with established HSV
- Mucosal immunity considerations in HSV vaccine design
- Regulatory challenges for HSV vaccines

Guest Editors

Prof. Dr. Lbachir BenMohamed

Institute for Immunology, School of Medicine, University of California
Irvine, Irvine, CA 92697, USA

Dr. Swayam Prakash

Institute for Immunology, School of Medicine, University of California
Irvine, Irvine, CA 92697, USA

Deadline for manuscript submissions

31 March 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/236937

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).